Slide 1: Third Quarter 2020 Operating & Financial Results Conference Call
Third Quarter 2020 Operating & Financial Results Conference Call https://ir.lanternpharma.com/ OCTOBER 29, 2020 4 PM Eastern
Slide 2: Forward-Looking Statements
LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 3: Key Topics
KEY TOPICS 1. Business Overview & Background Panna Sharma, CEO 2. Financial Results & Highlights Third Quarter 2020 David Margrave, CFO Operating and Financial Results Conference Call 3. Details on RADR Achieving 1 Billion Panna Sharma, CEO 4. Future Milestones & Outlook Panna Sharma, CEO 5. Q&A Ses
Slide 4: Lantern leverages A.I. to rescue and develop cancer therapies
Lantern leverages A.I. to rescue and develop cancer therapies and has the potential to transform the cost, risk and timeline of drug development Failed or Abandoned Drug Assets RADR® Responders Non-Responders • Big data (genomic, clinical, response) • Patient stratification based on A.I. enabled Dru
Slide 5: Lantern's Unique & Rapidly Developing Pipeline
Lantern’s Unique & Rapidly Developing Pipeline Indication Drug R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 Successfully partnered & out-licensed (Irofulven) Non-Small Cell Lung Cancer Targeting a sub-population in NSCLC of LP-300 Adenocarcinoma subtype (Focused on Never-Smokers
Slide 6: Summary Results of Operations (Unaudited)
Summary Results of Operations (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Operating expenses: General and administrative 1,100,719 441,251 2,117,290 977,300 Research and development 600,769 228,401 894,896 775,718 Total operating expenses 1,701,48
Slide 7: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary 09/30/2020 12/31/2019 (Unaudited) Cash $ 20,802,542 $1,232,030 Prepaid Expenses & Other Current Assets $1,672,802 788 Total Assets $ 22,492,952 $ 1,432,576 Total Liabilities $ 923,057 $ 489,292 Total Stockholders’ Equity $ 21,569,895 $ 943,284 Cash position of $20.
Slide 8: Entering "The Golden Age of A.I."
Entering “The Golden Age of A.I.” 10 Mega-Trends Setting The Stage for A.I. Led Transformation in Drug Development & Medicine ✦ Large-scale, relevant and readily available data-sets ✦ Methods, technologies and algorithms that are massively scalable ✦ Computing, storage and transmission continue expo
Slide 9: RADR Platform Key Features & Architecture
RADR® Platform Key Features & Architecture 85%+ RADR® rapidly identifies genetic & 1 Blinded biomarker signatures for precision prediction success oncology drug development, 55,900+ clinical response prediction and Cancer patient clinical histories CDx (companion diagnostic) enablement. 144+ Drug-tu
Slide 10: Growth in Data Drives Growth in Capabilities
Growth in Data Drives Growth in Capabilities The Data Powering our AI Platform has grown by 45x in the past 7 quarters * (Data points expressed in millions) • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number and mutation data • Clinical stage of tumor/
Slide 11: The RADR Platform Enables...
The RADR® Platform Enables... Rapid identification of potential compounds to Data Points Powering RADR® rescue and develop Scientific Value + Improved and more nuanced understanding of responder groups, and non-responder groups based on biological networks Feedback for potential mechanisms to
Slide 12: Biomarker Signature is Based on Statistical Significance and Biological Relevance
Biomarker Signature is Based on Statistical Significance and Biological Relevance RADR® automates machine-learning approaches in generating a biomarker based response signature that can be used throughout the lifecycle of therapy development: 1. Preclinical modeling and studies 2. Clarifying mechani
Slide 13: Collaboration Focused on Pancreatic Cancer for LP-184
Collaboration Focused on Pancreatic Cancer for LP-184 FOCUS: The Fox Chase collaboration is focused on advancing the targeted use of LP-184 in molecularly defined sub-types of pancreatic cancer. GOAL: The goal of the collaboration is to create a more biologically relevant and robust gene signature i
Slide 14: Collaboration Focused on Prostate Cancer for LP-184
Collaboration Focused on Prostate Cancer for LP-184 BACKDROP: The first phase of the joint research activities with Georgetown which began in the 4th quarter of 2019 generated strong evidence of the efficacy of LP-184 in certain solid tumors and linked the anti-tumor activity to the presence of spec
Slide 15: Key Value Building Objectives
Key Value Building Objectives Foundational Year Multiple Streams of Value Creation Advance Platform Launch Multiple Precision Trials Prepare Trial Launches Leverage Platform for Pharma Partners Prioritize Additional Compounds Secure Additional Compounds 4th Quarter 2020 & Early 2021 2021-22 ● Advanc
Slide 16: Upcoming Conference & Presentation Schedule
Upcoming Conference & Presentation Schedule Virtual Conferences 11/18/20 Benchmark Discovery One-on-One Conference Schedule Q4. 2020. 12/9/20 Benziga Global Small Cap Conference LTRN Unless otherwise noted, all events are virtual and based on confirmed registration and subject to the policies of the
Slide 17: Q&A
Q&A LTRN Operating & Financial Results Call OCTOBER 29, 2020 17